Evaluation of Smoked THC and CBD in Men and Women
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Aug 31, 2021
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of inhaled cannabis, specifically looking at two important compounds: THC (the chemical that makes you feel high) and CBD (which is thought to have calming effects). The researchers want to understand how these substances are processed in the body and how long they can be detected in oral fluid after smoking. The trial is open to both men and women aged 21 to 55 who use cannabis occasionally, about once a week or less, and are not currently trying to quit.
To participate, you should be in good health, with a Body Mass Index (BMI) between 18.5 and 34, and using a form of birth control if you're a woman. You won’t be eligible if you have a serious cannabis use disorder, any other major mental health issues, or if you've used other illegal drugs recently. If you join the study, you can expect to undergo various assessments to ensure your safety, and you'll be closely monitored during the trial to see how your body reacts to the cannabis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or non-pregnant and non-lactating females aged 21-55 years
- • Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,
- • Not currently seeking treatment for their cannabis use
- • Have a Body Mass Index from 18.5 - 34kg/m2.
- • Able to perform all study procedures
- • Must be using a contraceptive (hormonal or barrier methods)
- Exclusion Criteria:
- • Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine
- • Any other Axis I disorder
- • Report using other illicit drugs in the prior 4 weeks, other than cannabis.
- • Current use of any medications that may affect study outcomes
- • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
- • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
- • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
- • History of respiratory illness or current respiratory illness
- • Currently enrolled in another research protocol
- • Not using a contraceptive method (hormonal or barrier methods)
- • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Ziva Cooper, PhD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials